Dimensional Fund Advisors LP increased its stake in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 61.8% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 295,974 shares of the medical research company’s stock after buying an additional 113,074 shares during the period. Dimensional Fund Advisors LP’s holdings in PRA Health Sciences were worth $19,306,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. boosted its stake in PRA Health Sciences by 232.3% in the first quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock valued at $121,000 after buying an additional 1,289 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in PRA Health Sciences during the first quarter valued at about $136,000. First Bank & Trust boosted its stake in PRA Health Sciences by 1.7% in the first quarter. First Bank & Trust now owns 3,159 shares of the medical research company’s stock valued at $206,000 after buying an additional 54 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in PRA Health Sciences during the first quarter valued at about $208,000. Finally, Alambic Investment Management L.P. bought a new stake in PRA Health Sciences during the first quarter valued at about $228,000.

PRA Health Sciences, Inc. (NASDAQ:PRAH) traded up 0.53% on Friday, reaching $74.20. 781,983 shares of the company traded hands. The stock has a market capitalization of $4.65 billion, a price-to-earnings ratio of 47.90 and a beta of 0.45. The firm has a 50 day moving average price of $75.18 and a 200 day moving average price of $67.24. PRA Health Sciences, Inc. has a 52-week low of $48.42 and a 52-week high of $80.99.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Monday, August 7th. The medical research company reported $0.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.72 by $0.10. The firm had revenue of $457.90 million during the quarter, compared to the consensus estimate of $447.79 million. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. PRA Health Sciences’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 EPS. Equities research analysts predict that PRA Health Sciences, Inc. will post $3.18 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/pra-health-sciences-inc-prah-shares-bought-by-dimensional-fund-advisors-lp/1478954.html.

Several research analysts recently commented on PRAH shares. Jefferies Group LLC set a $73.00 price target on shares of PRA Health Sciences and gave the company a “buy” rating in a report on Thursday, June 1st. BidaskClub lowered shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Citigroup Inc. restated a “buy” rating and issued a $90.00 price target (up previously from $73.00) on shares of PRA Health Sciences in a report on Wednesday, June 28th. Bank of America Corporation started coverage on shares of PRA Health Sciences in a report on Monday, June 26th. They issued a “buy” rating and a $89.00 price target on the stock. Finally, SunTrust Banks, Inc. restated a “buy” rating on shares of PRA Health Sciences in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $78.00.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.